Evidence map›Paper›PMID 28889192›Full record

ArticleEuropean journal of pediatrics2017

The economic impact of prematurity and bronchopulmonary dysplasia.

María Álvarez-Fuente, Luis Arruza, Marta Muro, Carlos Zozaya, Alejandro Avila, Paloma López-Ortego, Carmen González-Armengod, Alba Torrent, Jose Luis Gavilán, María Jesús Del Cerro

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Association betweenFrontiers in pediatrics · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effect of vitamin D supplementation on incidence of bronchopulmonary dysplasia among preterm infants up to 36 weeks' gestational age.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025
    Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

María Álvarez-FuenteHospital Ramón y Cajal, Carrtera de Colmenar Viejo Km 9.1, 28034, Madrid, Spain. m.alvarez.fuente@salud.madrid.org.
Luis ArruzaHospital Clinico San Carlos, Madrid, Spain.
Marta MuroHospital Puerta de Hierro, Madrid, Spain.
Carlos ZozayaHospital La Paz, Madrid, Spain.
Alejandro AvilaComplejo Hospitalario de A Coruña, A Coruña, Spain.
Paloma López-OrtegoHospital La Paz, Madrid, Spain.
Carmen González-ArmengodHospital Puerta de Hierro, Madrid, Spain.
Alba TorrentHospital Vall D'Hebron, Barcelona, Spain.
Jose Luis GavilánHospital Virgen del Rocio, Seville, Spain.
María Jesús Del CerroHospital Ramón y Cajal, Carrtera de Colmenar Viejo Km 9.1, 28034, Madrid, Spain.
Hospital Universitario La Paz · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitario Ramón y Cajal · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínico San Carlos · ESHospital Universitario Virgen del Rocío · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchopulmonary dysplasia (BPD) is one of the most serious chronic lung diseases in infancy and one of the most important sequels of premature birth (prevalence of 15-50%). Our objective was to estimate the cost of BPD of one preterm baby, with no other major prematurity-related complications, during the first 2 years of life in Spain. Data from the Spanish Ministry of Health regarding costs of diagnosis-related group of preterm birth, hospital admissions and visits, palivizumab administration, and oxygen therapy in the year 2013 were analyzed. In 2013, 2628 preterm babies were born with a weight under 1500 g; 50.9% were males. The need for respiratory support was 2.5% needed only oxygen therapy, 39.5% required conventional mechanical ventilation, and 14.9% required high-frequency ventilation. The incidence of BPD was of 34.9%. The cost of the first 2 years of life of a preterm baby with BPD and no other major prematurity-related complications ranged between 45,049.81 € and 118,760.43 €, in Spain, depending on birth weight and gestational age. If the baby required home oxygen therapy or developed pulmonary hypertension, this cost could add up to 181,742.43 €.

conclusionPrematurity and BPD have an elevated cost, even for public health care systems. This cost will probably increase in the coming years if the incidence and survival of preterm babies keeps rising. The development of new therapies and preventive strategies to decrease the incidence of BPD and other morbidities associated with prematurity should be a priority. What is known: • Bronchopulmonary dysplasia (BPD) is a serious chronic lung disease related with premature birth. • BPD is an increasing disease due to the up-rise in the number of premature births. What is new: • The economic cost of preterm birth and BPD has never before been estimated in Spain nor published with European data. • Preterm babies with BPD and a good clinical outcome carry also an important economic and social burden.

Indexed as

Bronchopulmonary DysplasiaChild, PreschoolDatabases, FactualFemaleFollow-Up StudiesHealth Care CostsHumansIncidenceInfantInfant, NewbornInfant, PrematureMaleSpainBronchopulmonary dysplasiaPrematurity economic impactPreterm birthPulmonary hypertension

Identifiers

PMID28889192
OpenAlexW2756453606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.